Multifunctional nanoparticles for prostate cancer therapy

Expert Review of Anticancer Therapy

Volumn 9, Issue 2, 2009, Pages 211-221

  Salvador Morales, Carolina ^a,b   Gao, Weiwei ^a,b   Ghatalia, Pooja ^a   Murshed, Farhan ^a   Aizu, Wataru ^a,b   Langer, Robert ^b,c   Farokhzad, Omid C ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Chemotherapy; Gene therapy; Hyperthermia; Multifunctional; Nanoparticle; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CARDIOLIPIN; DOCETAXEL; DOXORUBICIN; GTI 2040; LIPOSOME; MACROGOL; NANOPARTICLE; NANOSHELL; OGX 011; PACLITAXEL; PEGAPTANIB; POLYGLACTIN; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA; VASCULOTROPIN 165;

ANGIONEUROTIC EDEMA; ANTIGEN EXPRESSION; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ERUPTION; DRUG PROTEIN BINDING; DRUG TRANSPORT; DYSPNEA; ENCAPSULATION; FLUSHING; HUMAN; HYPERSENSITIVITY REACTION; HYPERTHERMIC THERAPY; HYPOTENSION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PROSTATE CANCER; REVIEW; SIDE EFFECT; SUICIDE GENE THERAPY; TACHYCARDIA; THORAX PAIN; TUMOR VASCULARIZATION; URTICARIA; ANIMAL; CANCER STAGING; GENE THERAPY; MALE; METHODOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS; HYPERTHERMIA, INDUCED; MALE; NANOPARTICLES; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 64349103360     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.9.2.211     Document Type: Review

References (91)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J. Clin. 57(1), 43-66 (2007).
2. Rubin MA. Targeted therapy of cancer: new roles for pathologists-prostate cancer. Mod. Pathol. 21(2), S44-S55 (2008).
3. Gao J, Arnold JT, Isaacs JT. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res. 61(13), 5038-5044 (2001).
4. Culig Z, Hobisch A, Cronauer MV et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res.
5. (20), 5474-5478 (1994). 5 Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl Acad. Sci. USA 96(10), 5458-5463 (1999).
6. Damber JE, Aus G. Prostate cancer. Lancet 371(9625), 1710-1721 (2008).
7. Smith JR, Freije D, Carpten JD et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274(5291), 1371-1374 (1996).
8. Deutsch E, Maggiorella L, Eschwege P et al. Environmental, genetic, and molecular features of prostate cancer. Lancet Oncol. 5(5), 303-313 (2004).
9. Porkka KP, Visakorpi T. Molecular mechanisms of prostate cancer. Eur. Urol. 45(6), 683-691 (2004).
10. Dong JT. Prevalent mutations in prostate cancer. J. Cell Biochem. 97(3), 433-447 (2006).
11. Edwards SM, Eeles RA. Unravelling the genetics of prostate cancer. Am. J. Med. Genet. C. Semin. Med. Genet. 129(1), 65-73 (2004).
12. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748), 644-648 (2005).
13. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol. 26(17), 2862-2870 (2008).
14. Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl. Recept. Signal. 6(1), 1-12 (2008).
15. Wadih A, Trepel M, Zetter BR, Pasqualini R. Innovations in prostate cancer research. Cancer Res. 68(3), 635-638 (2008).
16. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the united states. J. Natl Cancer Inst. 98(16), 1134-1141 (2006).
17. Patel HR, Amodeo A, Joseph JV. Salvage laparoscopic surgery in advanced prostate cancer: is it possible or beneficial? Expert Rev. Anticancer Ther. 8(9), 1509-1513 (2008).
18. Aus SG. Cryosurgery for prostate cancer. J. Urol. 180(5), 1882-1883 (2008).
19. D'amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11), 969-974 (1998).
20. Bittner N, Merrick GS, Wallner KE, Butler WM. Interstitial brachytherapy should be standard of care for treatment of high-risk prostate cancer. Oncology 22(9), 995-1004 (2008).
21. Wo J, Zietman AL. Why does androgen deprivation enhance the results of radiation therapy? Urol. Oncol. 26(5), 522-529 (2008).
22. Chalasani V, Iansavichene AE, Lock M, Izawa JI. Salvage radiotherapy following radical prostatectomy. Int. J. Urol. (2008)
23. Tharp M, Hardacre M, Bennett R, Jones WT, Stuhldreher D, Vaught J. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy 7(3), 231-236 (2008).
24. EL Hayek OR, Alfer WJ, Reggio E et al. Prostate cryoablation: prospective analysis comparing high-and low-risk prostate cancer outcomes. Urol. Int. 81(2), 186-190 (2008).
25. Sahoo SK, Ma W, Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer 112(2), 335-340 (2004).
26. Hadaschik BA, Gleave ME. Therapeutic options for hormone-refractory prostate cancer in 2007. Urol. Oncol. 25(5), 413-419 (2007).
27. Yuan F. Transvascular drug delivery in solid tumors. Semin. Radiat. Oncol. 8(3), 164-175 (1998).
28. Wang A, Gu F, Zhang L et al. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin. Biol. Ther. 8(8), 1063-1070 (2008).
29. Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. 64(2), 704-710 (2004).
30. Farokhzad OC, Sangyong J, Langer R. Aptamer and cancer nanotechnology. In: Nanotechnology for Cancer Therapy. Amiji MM (Ed.). CRC Press Publisher, MA, USA 289-313 (2006).
31. Hattori Y, Maitani Y. Folate-linked lipid-based nanoparticles for targeted gene delivery. Curr. Drug Deliv. 2(3), 243-252 (2005).
32. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23(11), 1418-1423 (2005).
33. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751-760 (2007).
34. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263(5153), 1600-1603 (1994).
35. Gref R, Luck M, Quellec P et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B Biointerfaces 18(3-4), 301-313 (2000).
36. Gu F, Zhang L, Teply BA et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl Acad. Sci. USA 105(7), 2586-2591 (2008).
37. Cheng J, Teply BA, Sherifi I et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28(5), 869-876 (2007).
38. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 26(8), 442-449 (2008).
39. Ng EW, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5(2), 123-132 (2006).
40. Green LS, Jellinek D, Bell C et al. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem. Biol. 2(10), 683-695 (1995).
41. Jackson MW, Roberts JS, Heckford SE et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res. 62(3), 854-859 (2002).
42. Latil A, Bieche I, Pesche S. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int. J. Cancer. 89(2), 167-171 (2000).
43. Chu TC, Marks JW 3rd, Lavery LA. Aptamer: toxin conjugates that specifically target prostate tumor cells. Cancer Res. 66(12), 5989-5992 (2006).
44. Zhang L, Chan JM, Gu FX et al. Self assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2(8), 1696-1702 (2008).
45. Abouelfadel Z, Crawford ED. Leuprorelin depot injection: patient considerations in the management of prostatic cancer. Ther. Clin. Risk Manag. 4(2), 513-526 (2008).
46. Jang SH, Wientjes MG, LuD, Au JLS. Drug delivery and transport to solid tumors. Pharm. Res. 20(9), 1337-1350 (2003).
47. Stern JM, Stanfield J, Kabbani W, Hsieh JT, Cadeddu JA. Selective prostate cancer thermal ablation with laser activated gold nanoshells. J. Urol. 179(2), 748-753 (2008).
48. Martina MS, Fortin JP, Fournier L et al. Magnetic targeting of rhodamine-labeled superparamagnetic liposomes to solid tumors: in vivo tracking by fibered confocal fluorescence microscopy. Mol. Imaging 6(2), 140-146 (2007).
49. Theodossiou TA, Galanou MC, Paleos CM. Novel amiodarone-doxorubicin cocktail liposomes enhance doxorubicin retention and cytotoxicity in DU145 human prostate carcinoma cells. J. Med. Chem. 51(19), 6067-6074 (2008).
50. Kawai N, Futakuchi M, Yoshida T et al. Effect of heat therapy using magnetic nanoparticles conjugated with cationic liposomes on prostate tumor in bone. Prostate 68(7), 784-792 (2008).
51. Stauffer PR. Evolving technology for thermal therapy of cancer. Int. F. Hyperthermia 21(8), 731-744 (2005).
52. Johannsen M, Gneveckow U, Taymoorian K et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective Phase I trial. Int. J. Hyperthermia 23(3), 315-323 (2007).
53. Lehmann J, Natarajan A, Denardo GL et al. Nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cells. Cancer Biother. Radiopharm. 23(2), 265-271 (2008).
54. Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic nanoparticles. J. Biosci. Bioeng. 100(1), 1-11 (2005).
55. Wilhelm C, Fortin JP, Gazeau P. Tumour cell toxicity of intracellular hyperthermia mediated by magnetic nanoparticles. J. Nanosci. Nanotechnol. 7(8), 2933-2937 (2007).
56. Dass CR, Burton MA. Lipoplexes and tumours. A review. J. Pharm. Pharmacol. 51(7), 755-770 (1999).
57. Djavan B, Nasu Y. Prostate cancer gene therapy - what have we learned and where are we going? Rev. Urol. 3(4), 179-186 (2001).
58. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Natl Cancer Inst. 86(19), 1458-1462 (1994).
59. Gotoh A, Kao C, Ko SC, Hamada K, Liu TJ, Chung LW. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/C1P1 and p16CDKN4) in human prostate cancers. J. Urol. 158(2), 636-641 (1997).
60. Steinberg J, Oyasu R, Lang S et al. Intracellular levels of SGP-2(clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res. 3(10), 1707-1711 (1997).
61. Zellweger T, Chi K, Miyake H et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin. Cancer Res. 8(10), 3276-3284 (2002).
62. Chi KN, Eisenhauer E, Fazli L et al. Phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2>29>methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl Cancer Inst. 97(17), 1287-1296 (2005).
63. Fan H, Villegas C, Huang A et al. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res. 58(8), 1650-1653 (1998).
64. Sridhar SS, Canil CM, Hotte SJ et al. A Phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first line treatment in hormone refractory prostate cancer (HRPC). J. Clin. Oncol. 24(18S), 13015 (2006).
65. Concannon CG, Gorman AM, Samali A. On the role of Hsp27 in regulating apoptosis. Apoptosis 8(1), 61-70 (2003).
66. Schwab G, Chavany C, Duroux I et al. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl Acad. Sci. USA 91(22), 10460-10464 (1994).
67. Peng W, Anderson DG, Bao Y et al. Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumors. Prostate 67(8), 855-862 (2007).
68. Chumakova OV, Liopo AV, Andreev VG et al. Composition of PLGA and PEI/DNA nanoparticles improves ultrasoundmediated gene delivery in solid tumors in vivo. Cancer Lett. 261(2), 215-225 (2008).
69. De Smedt SC, Demeester SCJ, Hennink WE. Cationic polymer based gene delivery systems. Pharm. Res. 17(2), 113-126 (2000).
70. Prabha S, Labhasetwar V. Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. Pharm. Res. 21(2), 354-364 (2004).
71. Hattori Y, Maitani Y. Low-molecular-weight polyethylenimine enhanced gene transfer by cationic cholesterol-based nanoparticle vector. Biol. Pharm. Bull. 30(9), 1773-1778 (2007).
72. Tsai H, Werber J, Davia MO et al. Reduced connexin 43 expression in high grade, human prostatic adenocarcinoma cells. Biochem. Biophys. Res. Commun. 227(1), 64-69 (1996).
73. Takei Y, Kadomatsu K, Yuzawa Y et al. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 64(10), 3365-3370 (2004).
74. Pal A, Ahmad A, Khan S et al. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate. Int. J. Oncol. 26(4), 1087-1091 (2005).
75. Li SD, Chen YC, Hackett MJ, Huang L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol. Ther. 16(1), 163-169 (2008).
76. Teixeira AL, Ribeiro R, Cardoso D et al. Genetic polymorphism in EGFR is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin. Cancer Res. 14(11), 3367-3371 (2008).
77. Lechardeur D, Lukacs GL. Intracellular barriers to non-viral gene transfer. Curr. Gene. Ther. 2(2), 183-194 (2002).
78. Shubik P. Vascularization of tumors: a review. J. Cancer Res. Clin. Oncol. 103(3), 211-226 (1982).
79. Heuser LS, Miller FN. Differential macromolecular leakage from the vasculature of tumors. Cancer 57(3), 461-464 (1986).
80. Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl Cancer Inst. 81(8), 570-576 (1989).
81. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60(9), 2497-2503 (2000).
82. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 47(12), 3039-3051 (1987).
83. Moghimi SM. Passive targeting of solid tumor: pathophysiological principles and physicochemical aspects of delivery systems. In: Nanotechnology for Cancer Therapy. Amiji MM (Ed.). CRC Press Publisher, MA, USA 11-16 (2006).
84. Szebeni J, Muggia FM, Alving CR. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Natl Cancer Inst. 90(4), 300-306 (1998).
85. Moghimi SM, Hamad I, Andresen TL, Jorgensen K, Szebeni J. Methylation of the phosphate oxygen moiety of phospholipidmethoxy(polyethylene glycol)conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 20(14), 2591-2593 (2006).
86. McNamara II JO, Andrechek ER, Wang Y et al. Cell type-specific delivery of siRNA with aptamer-siRNA chimeras. Nat. Biotechnol. 24(8), 1005-1015 (2006).
87. Weng KC, Noble CO, Papahadjopoulos-Sternberg B et al. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett. 8(9), 2851-2857 (2008).
88. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5(4), 487-495 (2008).
89. Salvador-Morales C, Basiuk EV, Green ML, Sim RB. Effects of covalent functionalization on the biocompatibility characteristics of multi-walled carbon nanotubes. J. Nanosci. Nanotechnol. 8(5), 2347-2356 (2008).
90. Petrylak D. Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int. 96(2), 41-46 (2005).
91. Concannon CG, Gorman AM, Samali A. On the role of Hsp27 in regulating apoptosis. Apoptosis 8 (1), 61-70 (2003).